SOUTH SAN FRANCISCO, Calif. , Nov. 26, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc . (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno , the company's chief financial officer, will present a company overview at the Piper Sandler 37 th Annual Healthcare Conference on Wednesday, December 3, 2025 , at 8:30 am ET . To access the live... Read More

Olutasidenib continued to demonstrate durable efficacy and a manageable safety profile in a broad range of patients with R/R mIDH1 AML, including those previously treated with venetoclax-based regimens Rigel advances its strategic collaborations to further evaluate olutasidenib with the activation of a fifth study with MD Anderson and enrollment of the first patient in the CONNECT TarGeT-D study SOUTH SAN FRANCISCO, Calif. ,... Read More

SOUTH SAN FRANCISCO, Calif. , Nov. 12, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez , the company's president and CEO, will present a company overview at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025 at 10:00 a.m. GMT ( 5:00 a.m. ET ). To access the... Read More

Third quarter 2025 total revenue of approximately $69.5 million , including record net product sales of $64.1 million and contract revenues from collaborations of $5.4 million Generated $27.9 million of net income in the third quarter of 2025 Completed enrollment in the dose escalation phase and enrolled the first patient in the dose expansion phase of the ongoing Phase 1b study evaluating R289, Rigel's dual IRAK1/4... Read More

Oral presentation to feature updated data from the ongoing Phase 1b study evaluating R289, Rigel's dual IRAK1/4 inhibitor, in patients with relapsed or refractory lower-risk MDS Four poster presentations will exhibit new REZLIDHIA ® (olutasidenib) data in patients with R/R mIDH1 AML SOUTH SAN FRANCISCO, Calif. , Nov. 3, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company... Read More

SOUTH SAN FRANCISCO, Calif. , Oct. 29, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc . (Nasdaq: RIGL) today announced that it will report its third quarter 2025 financial results after market close on Tuesday, November 4 , 2025. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time ( 1:30 p.m. Pacific Time ) to discuss the financial results and give an update... Read More

Dose expansion phase will determine the recommended Phase 2 dose of R289 for patients with transfusion dependent R/R lower-risk MDS SOUTH SAN FRANCISCO, Calif. , Oct. 8, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the first patient has been enrolled in the dose expansion phase of the ongoing Phase 1b... Read More

SOUTH SAN FRANCISCO, Calif. , Oct. 3, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4).... Read More

SOUTH SAN FRANCISCO, Calif. , Aug. 26, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez , the company's president and chief executive officer, and Dean Schorno , the company's chief financial officer, will participate in the following investor conferences in September: Citi's 2025... Read More

Second quarter 2025 total revenue of approximately $101.7 million , which includes net product sales of $58.9 million and contract revenues from collaborations of $42.7 million Completed enrollment in the dose escalation part of the ongoing Phase 1b study evaluating R289, a dual IRAK1/4 inhibitor, in patients with R/R lower-risk MDS Generated $59.6 million of net income in the second quarter of 2025 Updated 2025 Outlook:... Read More

SOUTH SAN FRANCISCO, Calif. , July 29, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2025 financial results after market close on Tuesday, August 5 , 2025. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time ( 1:30 p.m. Pacific Time ) to discuss the financial results and give an update... Read More

SOUTH SAN FRANCISCO, Calif. , July 7, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4).... Read More

SOUTH SAN FRANCISCO, Calif. , May 28, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez , the company's president and CEO, will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 12:50 p.m. ET in New York, NY . To access the live webcast... Read More

Final data from the GAVRETO ® (pralsetinib) Phase 1/2 ARROW study in RET fusion-positive NSCLC and other solid tumors Supportive data for REZLIDHIA ® (olutasidenib) utilization in patients with mIDH1 R/R AML SOUTH SAN FRANCISCO, Calif. , May 22, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced seven upcoming... Read More

First quarter 2025 total revenue of approximately $53.3 million , which includes net product sales of $43.6 million and contract revenues from collaborations of $9.8 million Generated $11.4 million of net income in the first quarter of 2025 R289 granted Orphan Drug designation for the treatment of MDS and Fast Track designation for the treatment of previously-treated transfusion dependent lower-risk MDS by the FDA 2025... Read More

SOUTH SAN FRANCISCO, Calif. , April 29, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2025 financial results after market close on Tuesday, May 6 , 2025. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time ( 1:30 p.m. Pacific Time ) to discuss the financial results and give an update on... Read More

SOUTH SAN FRANCISCO, Calif. , April 4, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4).... Read More

SOUTH SAN FRANCISCO, Calif. , March 27, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has entered into a settlement agreement with Annora Pharma Private Ltd., Hetero Labs Ltd., and Hetero USA , Inc. (collectively "Annora") resolving patent litigation related to Rigel's product TAVALISSE ® (fostamatinib disodium hexahydrate). The litigation resulted from submission by Annora of an... Read More

SOUTH SAN FRANCISCO, Calif. , March 10, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Mark W. Frohlich, M.D. to its Board of Directors. Dr. Frohlich is a medical oncologist and brings more than 25 years of experience developing cellular immunotherapies to treat cancer, including deep expertise in clinical drug development and translational research, and portfolio... Read More

Fourth quarter 2024 total revenue of approximately $57.6 million , which includes TAVALISSE ® net product sales of $31.0 million , REZLIDHIA ® net product sales of $7.4 million and GAVRETO ® net product sales of $8.1 million 2024 total revenue of approximately $179.3 million , which includes TAVALISSE ® net product sales of $104.8 million , REZLIDHIA ® net product sales of $23.0 million and GAVRETO ® net product sales of... Read More

SOUTH SAN FRANCISCO, Calif. , Feb. 25, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2024 financial results after market close on Tuesday, March 4 , 2025. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time ( 1:30 p.m. Pacific Time ) to discuss the financial results and... Read More

First patient enrolled in NIH/NHLBI-sponsored Phase 1 Study of fostamatinib, Rigel's oral SYK inhibitor SOUTH SAN FRANCISCO, Calif. , Jan. 22, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the first patient has been enrolled in a Phase 1 study evaluating the safety and tolerability of escalating doses of fostamatinib, the company's oral spleen tyrosine kinase (SYK) inhibitor, in patients... Read More

Preliminary fourth quarter 2024 total revenue of approximately $57.6 million which includes TAVALISSE ® net product sales of $31.0 million , REZLIDHIA ® net product sales of $7.4 million and GAVRETO ® net product sales of $8.1 million R289 granted Orphan Drug designation by the FDA for the treatment of MDS Rigel anticipates 2025 total revenue of approximately $200 to $210 million SOUTH SAN FRANCISCO, Calif. , Jan. 13, 2025... Read More

SOUTH SAN FRANCISCO, Calif. , Jan. 9, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to R289 for the treatment of myelodysplastic syndromes (MDS). R289 1 , Rigel's potent and selective dual inhibitor of IRAK1 and IRAK4, is... Read More

SOUTH SAN FRANCISCO, Calif. , Jan. 8, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez , the company's president and CEO, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 8:15 a.m. PT ( 11:15 a.m. ET ) in San Francisco,... Read More

SOUTH SAN FRANCISCO, Calif. , Jan. 3, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4).... Read More

R289 was generally well tolerated and demonstrated signs of preliminary clinical activity in elderly heavily pretreated LR-MDS patients RBC-TI/HI-E responses occurred in 40% of evaluable TD patients receiving R289 doses ≥500 mg QD SOUTH SAN FRANCISCO, Calif. , Dec. 9, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today... Read More

SOUTH SAN FRANCISCO, Calif. , Dec. 2, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to R289 for the treatment of patients with previously-treated transfusion dependent lower-risk myelodysplastic syndrome (LR-MDS). R289 1 ,... Read More

SOUTH SAN FRANCISCO, Calif. , Nov. 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno , the company's chief financial officer, will present a company overview at the Jefferies London Healthcare Conference on Tuesday, November 19 , at 9:30 am GMT ( 4:30 am EST ). To access the live webcast... Read More

Third quarter total revenue of $55.3 million , which includes TAVALISSE ® net product sales of $26.3 million , REZLIDHIA ® net product sales of $5.5 million and GAVRETO ® net product sales of $7.1 million Entered into an agreement with Kissei to develop and commercialize REZLIDHIA in all potential indications in Japan , the Republic of Korea and Taiwan , recording an upfront cash payment of $10.0 million during the third... Read More

Initial data from the ongoing Phase 1b study evaluating R289, a dual IRAK1/4 inhibitor, in LR-MDS Additional data for REZLIDHIA ® (olutasidenib) in patients with mIDH1 AML and MDS SOUTH SAN FRANCISCO, Calif. , Nov. 5, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced upcoming presentations of six posters... Read More

SOUTH SAN FRANCISCO, Calif. , Oct. 31, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2024 financial results after market close on Thursday, November 7 , 2024. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time ( 1:30 p.m. Pacific Time ) to discuss the financial results and give an update... Read More

SOUTH SAN FRANCISCO, Calif. , Oct. 24, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced it is issuing a Dear Health Care Provider (DHCP) letter related to a new safety signal for GAVRETO ® (pralsetinib) after consultation with the U.S. Food and Drug Administration (FDA). GAVRETO is for the treatment... Read More

ST. LOUIS, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Optime Care, a nationally recognized specialty pharmacy and an AscellaHealth Company, today announces an expanded arrangement with Rigel Pharmaceuticals, Inc , effective October 14, 2024, to include commercial distribution of TAVALISSE ® (fostamatinib). TAVALISSE is an oral medicine that can help patients manage chronic immune thrombocytopenia (ITP) by protecting their platelets... Read More

SOUTH SAN FRANCISCO, Calif. , Oct. 4, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted... Read More

SOUTH SAN FRANCISCO, Calif. , Sept. 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez , the company's president and CEO, will present a company overview at the Cantor Global Healthcare Conference on Thursday, September 19 , at 9:10 am ET in New York, NY . To access the live webcast or... Read More

First trial in Rigel's multi-year strategic development alliance with MD Anderson Phase 1b /2 trial of decitabine and venetoclax in combination with Rigel's targeted mIDH1 inhibitor REZLIDHIA for patients with mIDH1 AML SOUTH SAN FRANCISCO, Calif. , Sept. 5, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced... Read More

Kissei gains exclusive rights to develop and commercialize olutasidenib in all current and potential indications in Japan , the Republic of Korea and Taiwan Rigel will receive an upfront cash payment of $10.0 million with the potential for up to $152.5 million in future development, regulatory, and commercial milestone payments Rigel to receive product transfer price payments in the mid-twenty to lower-thirty percent range... Read More

SOUTH SAN FRANCISCO, Calif. , Aug. 29, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno , the company's chief financial officer, will participate in the following investor conferences in September: 2024 Wells Fargo Healthcare Conference, Boston, MA Mr. Schorno will participate in one-on-one... Read More

Second quarter total revenue of $36.8 million , which includes TAVALISSE ® net product sales of $26.4 million , REZLIDHIA ® net product sales of $5.2 million and GAVRETO ® net product sales of $1.9 million Successfully completed NDA transfer of GAVRETO for the treatment of RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer, with product available from Rigel beginning June 27,... Read More

SOUTH SAN FRANCISCO, Calif. , July 30, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2024 financial results after market close on Tuesday, August 6 , 2024. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time ( 1:30 p.m. Pacific Time ) to discuss the financial results and give an update... Read More

SOUTH SAN FRANCISCO, Calif. , July 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel... Read More

SOUTH SAN FRANCISCO, Calif. , June 25, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will effect a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-10 (the "Reverse Stock Split"), effective at 12:01 a.m. Eastern Time on Thursday , June 27, 2024. The company's common stock will begin trading on a post-split basis on The Nasdaq Global Select... Read More

GAVRETO will be available from Rigel in the U.S. beginning June 27, 2024 SOUTH SAN FRANCISCO, Calif. , June 24, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced the completion of the transfer to Rigel of the New Drug Application (NDA) for GAVRETO ® (pralsetinib) for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung... Read More

Oral presentation highlighting final five-year efficacy data from the registrational Phase 2 trial of REZLIDHIA ® (olutasidenib) in heavily pretreated patients with R/R mIDH1 AML, including those receiving prior venetoclax New data shows clinically meaningful effect of olutasidenib in patients with mIDH1 AML secondary to MPN and as bridge-to-transplant treatment in patients with R/R mIDH1 AML SOUTH SAN FRANCISCO, Calif. ,... Read More

Long-term efficacy data from the registrational Phase 2 trial of REZLIDHIA ® (olutasidenib) in heavily pretreated patients with R/R mIDH1 AML, including those receiving prior venetoclax Data from a subgroup analyses of elderly R/R mIDH1 AML patients treated with olutasidenib shows consistent CR/CRh results Overview of the Phase 1b trial of R289 in patients with lower-risk MDS SOUTH SAN FRANCISCO, Calif. , June 3, 2024... Read More

SOUTH SAN FRANCISCO, Calif. , May 30, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez , the company's president and CEO, will present a company overview at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:30 am ET in New York, NY . To access the live webcast or archived recording, visit the Investor Relations section of the company's website at... Read More

Oral presentation of final five-year results from the registrational Phase 2 trial in R/R mIDH1 AML patients reinforces REZLIDHIA ® (olutasidenib) efficacy in heavily pretreated patients, including those receiving prior venetoclax Other key posters further support the efficacy of REZLIDHIA ® (olutasidenib) in elderly, transplant-eligible, and post-MPN patients with AML SOUTH SAN FRANCISCO, Calif. , May 23, 2024 /PRNewswire/... Read More

First quarter 2024 total revenue of $29.5 million , which includes TAVALISSE ® net product sales of $21.1 million and REZLIDHIA ® net product sales of $4.9 million Expanded Rigel's portfolio with acquisition of GAVRETO ® , a U.S. marketed product for RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer Appointed Lisa Rojkjaer, M.D. as Chief Medical Officer Conference call and... Read More

SOUTH SAN FRANCISCO, Calif. , April 30, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2024 financial results after market close on Tuesday, May 7 , 2024. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time ( 1:30 p.m. Pacific Time ) to discuss the financial results and give an update on... Read More

SOUTH SAN FRANCISCO, Calif. , April 10, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel... Read More

Olutasidenib induced durable composite complete remission in 43.8% of patients relapsed or refractory to prior venetoclax-based regimens Safety was consistent with the overall profile of olutasidenib Olutasidenib may offer a valuable treatment option for patients with mIDH1 previously treated with venetoclax SOUTH SAN FRANCISCO, Calif. , April 4, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced... Read More

SOUTH SAN FRANCISCO, Calif. , March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, M.D. as Executive Vice President and Chief Medical Officer. Dr. Rojkjaer is an industry veteran with over 20 years of clinical development, regulatory, and medical affairs experience with a focus on hematology and oncology. She is a board-certified hematologist with an... Read More

Fourth quarter 2023 Total Revenue of $35.8 million which includes TAVALISSE ® net product sales of $25.7 million and REZLIDHIA ® net product sales of $3.9 million Expanded product portfolio with acquisition of U.S. rights to GAVRETO ® , an FDA approved targeted therapy for the treatment of RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer Conference call and webcast scheduled... Read More

SOUTH SAN FRANCISCO, Calif. , Feb. 27, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2023 financial results after market close on Tuesday, March 5 , 2024. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time ( 1:30 p.m. Pacific Time ) to discuss the financial results and... Read More

GAVRETO ® (pralsetinib) is an FDA approved targeted therapy for the treatment of RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer Acquisition of established U.S. marketed product further expands Rigel's portfolio and leverages Rigel's existing infrastructure in both the institutional and community settings GAVRETO generated ~$28M in U.S. net product sales in 2023 SOUTH SAN... Read More

Preliminary fourth quarter 2023 total revenue of approximately $35.7 million which includes record TAVALISSE ® net product sales of $25.7 million and REZLIDHIA ® net product sales of $3.9 million Strategic alliance with MD Anderson to advance REZLIDHIA in AML and other cancers Collaboration with CONNECT to evaluate REZLIDHIA in a Phase 2 clinical trial in glioma SOUTH SAN FRANCISCO, Calif. , Jan. 8, 2024 /PRNewswire/ --... Read More

SOUTH SAN FRANCISCO, Calif. , Jan. 5, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted... Read More

SOUTH SAN FRANCISCO, Calif. , Jan. 4, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a collaboration with CONNECT, an international collaborative network of pediatric cancer centers, to conduct a Phase 2 clinical trial to evaluate REZLIDHIA ® (olutasidenib) in combination with temozolomide as maintenance therapy in newly diagnosed pediatric and young adult patients with high-grade glioma... Read More

SOUTH SAN FRANCISCO, Calif. , Jan. 3, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez , the company's president and CEO, will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 12:00 p.m. PT in San Francisco, CA. To access the live webcast or archived recording, visit the Investor Relations section of the... Read More

SOUTH SAN FRANCISCO, Calif. and HOUSTON , Dec. 8, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and The University of Texas MD Anderson Cancer Center (MD Anderson) today announced a multi-year strategic development collaboration to expand the evaluation of REZLIDHIA ® (olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The alliance brings together MD Anderson's clinical research... Read More

Third quarter 2023 Total Revenue of $28.1 million which includes record TAVALISSE ® net product sales of $24.5 million and REZLIDHIA ® net product sales of $2.7 million New data on olutasidenib in mIDH1 relapsed or refractory acute myeloid leukemia to be presented at ASH Annual Meeting Conference call and webcast scheduled today at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif. , Nov. 7, 2023 /PRNewswire/ -- Rigel... Read More

SOUTH SAN FRANCISCO, Calif. , Nov. 6, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno , the company's chief financial officer, will present a company overview at the Jefferies 2023 London Healthcare Conference on Tuesday, November 14, 2023 at 3:30 p.m. GMT ( 10:30 a.m. EST ). To access the live webcast or archived recording, visit the Investor Relations section of the... Read More

Growing body of data on REZLIDHIA ® (olutasidenib) in mIDH1 relapsed or refractory (R/R) acute myeloid leukemia (AML) patients New data on olutasidenib in patients with mIDH1 myelodysplastic syndromes/neoplasms (MDS) SOUTH SAN FRANCISCO, Calif. , Nov. 2, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the upcoming presentation of four posters highlighting data from their commercial and... Read More

SOUTH SAN FRANCISCO, Calif. , Oct. 31, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2023 financial results after market close on Tuesday, November 7 , 2023. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time ( 1:30 p.m. Pacific Time ) to discuss the financial results and give an update... Read More

Provides Update on ACTIV-4 Host Tissue Trial SOUTH SAN FRANCISCO, Calif. , Oct. 11, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced an upcoming oral presentation highlighting data from the FOCUS Phase 3 clinical trial of fostamatinib in hospitalized COVID-19 patients without respiratory failure who have certain high-risk prognostic factors at IDWeek 2023 being held October 11-15, 2023 , in... Read More

SOUTH SAN FRANCISCO, Calif. , Oct. 6, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted... Read More

SOUTH SAN FRANCISCO, Calif. , Sept. 20, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno , the company's chief financial officer, will present a company overview at the Cantor Global Healthcare Conference on Wednesday, September 27, 2023 at 3:35 p.m. ET in New York, NY . To access the live webcast or archived recording, visit the Investor Relations section of the company's... Read More

SOUTH SAN FRANCISCO, Calif. , Aug. 30, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez , the company's president and chief executive officer, and Dean Schorno , the company's chief financial officer, will participate in the following investor conferences in September: 2023 Wells Fargo Healthcare Conference, September 6-8, 2023 , Boston, MA Raul Rodriguez will present a... Read More

Second quarter 2023 Total Revenue of $26.9 million which includes TAVALISSE ® net product sales of $21.3 million and REZLIDHIA ® net product sales of $2.6 million Development programs continue to advance with completion of target enrollment in cohort 2 of Phase 1b trial of R289 in lower-risk MDS and initiation of Phase 2a trial of R552 in rheumatoid arthritis by partner, Eli Lilly Conference call and webcast scheduled today... Read More

SOUTH SAN FRANCISCO, Calif. , July 25, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2023 financial results after market close on Tuesday, August 1 , 2023. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time ( 1:30 p.m. Pacific Time ) to discuss the financial results and give an update... Read More

SOUTH SAN FRANCISCO, Calif. , July 5, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4).... Read More

Durable remissions observed in patients relapsed or refractory to prior venetoclax-based regimens Data featured in a poster presentation at the European Hematology Association (EHA) 2023 Hybrid Congress SOUTH SAN FRANCISCO, Calif. , June 7, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced promising data from an analysis of the Phase 2 study evaluating REZLIDHIA ® (olutasidenib), a potent,... Read More

Review article examines the preclinical and clinical development, and the role of olutasidenib in the m IDH1 AML treatment landscape. Authors conclude, "The approval of olutasidenib is a critical addition to the m IDH1 AML treatment landscape with encouragingly durable responses." SOUTH SAN FRANCISCO, Calif. , June 6, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced an expert review article in... Read More

SOUTH SAN FRANCISCO, Calif. , June 1, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced an upcoming poster presentation highlighting the Company's IRAK1/4 program at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 2-6, 2023 , in Chicago, IL , and virtually. Rigel continues to advance the open-label, Phase 1b clinical trial of R289 1 , an investigational,... Read More

SOUTH SAN FRANCISCO, Calif. , May 31, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez , the company's president and chief executive officer, will present on Wednesday, June 7, 2023 at 2:30 p.m. ET at the Jefferies 2023 Global Healthcare Conference, being held June 7-9, 2023 in New York, NY . To access the live and subsequent archived webcast, visit the Investor Relations... Read More

First quarter 2023 Total Revenue of $26.1 million which includes TAVALISSE ® net product sales of $22.3 million and REZLIDHIA ® net product sales of $1.5 million Global expansion of TAVALISSE in ITP with Japanese launch by partner Kissei Conference call and webcast scheduled today at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif. , May 2, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported... Read More

SOUTH SAN FRANCISCO, Calif. , April 25, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2023 financial results after market close on Tuesday, May 2 , 2023. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time ( 1:30 p.m. Pacific Time ) to discuss the financial results and give an update on... Read More

SOUTH SAN FRANCISCO, Calif. , April 6, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4).... Read More

Fourth quarter 2022 Total Revenue of $51.3 million which includes TAVALISSE ® net product sales of $21.9 million and REZLIDHIA ™ net product sales of $0.9 million REZLIDHIA U.S. commercial launch continues to progress and is supported by recent addition to NCCN Guidelines ® for AML Conference call and webcast scheduled today at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif. , March 7, 2023 /PRNewswire/ -- Rigel... Read More

SOUTH SAN FRANCISCO, Calif. , Feb. 28, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2022 financial results after market close on Tuesday, March 7, 2023 . Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time ( 1:30 p.m. Pacific Time ) to discuss the financial results and... Read More

REZLIDHIA induced durable remissions in adult patients with mIDH1 R/R AML SOUTH SAN FRANCISCO, Calif. , Feb. 2, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a peer-reviewed publication of data in Blood Advances , which summarizes clinical results from the Phase 2 registrational study of REZLIDHIA™ (olutasidenib), a potent, selective, oral, small-molecule inhibitor of mutant isocitrate... Read More

SOUTH SAN FRANCISCO, Calif. , Jan. 18, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that REZLIDHIA ™ (olutasidenib) has been added by the National Comprehensive Cancer Network ® (NCCN ® ) to the latest NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) for acute myeloid leukemia (AML). REZLIDHIA (olutasidenib) is now included as a recommended targeted therapy for adult... Read More

REZLIDHIA™ U.S. FDA approval and commercial launch for the treatment of adult patients with relapsed or refractory AML with susceptible IDH1 mutation Preliminary fourth quarter 2022 Total Revenue of approximately $51.3 million which includes TAVALISSE ® preliminary net product sales of approximately $21.9 million and REZLIDHIA preliminary net product sales of approximately $0.9 million Continued global expansion of TAVALISSE... Read More

SOUTH SAN FRANCISCO, Calif. , Dec. 22, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that REZLIDHIA™ (olutasidenib) capsules are available in the U.S. by prescription for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. REZLIDHIA is an oral, small... Read More

R289 is an investigational, oral, inhibitor of interleukin receptor-associated kinases 1 and 4 (IRAK1/4), being studied as a potentially differentiated approach to treating lower-risk MDS SOUTH SAN FRANCISCO, Calif. , Dec. 15, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced it dosed the first patient in its Phase 1b study of R289, an IRAK1/4 dual inhibitor, in patients with lower-risk... Read More

SOUTH SAN FRANCISCO, Calif. , Dec. 9, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to an employee's entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4).... Read More

REZLIDHIA is a potentially market-leading, oral, mutant isocitrate dehydrogenase-1 (mIDH1) inhibitor Phase 2 registrational data supporting the approval showed a 35% CR+CRh rate in mIDH1 R/R AML patients with a median duration of response of 25.9 months Conference call and webcast to be held today at 6:30 p.m. ET SOUTH SAN FRANCISCO, Calif. , Dec. 1, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today... Read More